Hong Kong Stock Movement | Haixi New Drug (02637.HK) surged over 14% in the morning as HX9428 was approved to initiate Phase II clinical trials in the U.S. while also launching clinical trials in China.

According to Zhitong Finance APP, Haixi New Drug (02637.HK) rose over 14% in early trading, and as of the time of publication, it is up 7.35%, priced at HKD 200, with a trading volume of HKD 14.8511 million.